Calcimedica Inc (CALC)

$0.82 +0.19 (30.29%)
Market Cap 12.89M
Revenue (ttm) 0.00
Net Income (ttm) -29.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -2.27
Volume 2,931,600
Avg Vol 1,434,958
Day's Range N/A - N/A
Shares Out 15.80M
Stochastic %K 71%
Beta 0.97
Analysts Strong Sell
Price Target $10.33

Company Profile

CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 5500
Address:
505 Coast Boulevard South, Suite 307, La Jolla, United States
Zardiw
Zardiw Jun. 28 at 5:12 PM
#DDAmanda Chart on $TSLA. Your thoughts? Watching these too: $ILLR $CALC $LVWR Check our 4th of July Special! https://DDAmanda.com
0 · Reply
Dan_o
Dan_o Jun. 28 at 12:51 PM
$CALC Part 1 - To follow is an email I sent to $CALC investor relations back in Feb. when the stock price crashed. I shared the story of $RZLT that recently crashed from $10 to $1 after a lead trial failed . Their management and board showed confidence by buying more shares. $RZLT is still developing a pipeline and has ZERO, $0, revenue. Their stock price is now $5 a share. I will be a buyer at market open on Monday and will hold my position. The next immediate catalyst will be staying over $1 for ten days.
0 · Reply
Dan_o
Dan_o Jun. 28 at 12:50 PM
$CALC Part 2 - Email: I cannot think of a more motivated group of people than the current $CALC management. You own 52% of the shares. Before the dip the value was $37 mil and current value is $4 mil. I estimate you collectively have a cost bases of about $18 mil. If you could only learn from Rezolute Inc., $RZLT, management. Their share price dropped from $10 to $1 in December in less than one day. Management stepped in and purchased the stock at a deep discount like I am doing. In a little over a month and a half the Rezolute price per share peaked at $4 and is holding above $3.5 a share.
0 · Reply
MikeCaymanTrades
MikeCaymanTrades Jun. 27 at 8:38 PM
$CALC big open gap above 1.00
0 · Reply
Zardiw
Zardiw Jun. 27 at 5:29 PM
$SDOT - #DDAmanda Chart. Not making a call on this one, just sharing what the scanner found. Also keeping an eye on: $ARL $WSHP $CALC Check our 4th of July Special! https://DDAmanda.com
1 · Reply
Zardiw
Zardiw Jun. 27 at 4:58 PM
#DDAmanda Chart on $INLF. Setting up or breaking down? Also keeping an eye on: $SDOT $CALC $RYOJ Check our 4th of July Special! https://DDAmanda.com
0 · Reply
pablo4
pablo4 Jun. 26 at 9:32 PM
$CALC I'm resharing one of my 3 back to back posts from last night. IMO, today's action was to be expected. Although it was a pleasant surprise being so soon...the next day, the buyers were bound to step in. Management showed its willingness to risk more of its own capital on this science (business). That was not to be ignored....IMO!
0 · Reply
topstockalerts
topstockalerts Jun. 26 at 8:36 PM
$CALC this one earned a closer look today
0 · Reply
pablo4
pablo4 Jun. 26 at 8:10 PM
$CALC Fidelity shows a close of .8159.
1 · Reply
MUBSN
MUBSN Jun. 26 at 7:44 PM
$CALC there we go
1 · Reply
Latest News on CALC
CalciMedica announces $49M private placement

2026-06-24T11:11:04.000Z - 4 days ago

CalciMedica announces $49M private placement

CalciMedica announces FDA review of protocol amendment for Kourage trial

2026-06-24T11:06:02.000Z - 4 days ago

CalciMedica announces FDA review of protocol amendment for Kourage trial

CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program

Jun 24, 2026, 7:01 AM EDT - 4 days ago

CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program

CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data

Jun 24, 2026, 7:00 AM EDT - 4 days ago

CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data

CalciMedica Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 6 weeks ago

CalciMedica Quarterly report: Q1 2026

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

May 12, 2026, 7:00 AM EDT - 6 weeks ago

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica price target lowered to $10 from $20 at Oppenheimer

2026-03-05T13:27:54.000Z - 4 months ago

CalciMedica price target lowered to $10 from $20 at Oppenheimer

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

Mar 3, 2026, 7:00 AM EST - 4 months ago

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Registration statement: Registration Filing

Mar 3, 2026, 7:00 AM EST - 4 months ago

CalciMedica Registration statement: Registration Filing

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

Jan 28, 2026, 7:00 AM EST - 5 months ago

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation

CalciMedica Registration statement: Registration Filing

Nov 13, 2025, 7:00 AM EST - 8 months ago

CalciMedica Registration statement: Registration Filing

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Nov 12, 2025, 7:01 AM EST - 8 months ago

CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

Nov 12, 2025, 7:00 AM EST - 8 months ago

CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

Oct 14, 2025, 7:00 AM EDT - 9 months ago

CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 10 months ago

CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Aug 12, 2025, 7:00 AM EDT - 11 months ago

CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 7:00 AM EDT - 1 year ago

CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

Jun 25, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

Jun 12, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting

CalciMedica Proxy statement: Proxy Filing

Jun 9, 2025, 8:00 AM EDT - 1 year ago

CalciMedica Proxy statement: Proxy Filing

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

May 14, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

CalciMedica Proxy statement: Proxy Filing

CalciMedica Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

CalciMedica Proxy statement: Proxy Filing

CalciMedica Announces Presentations at Upcoming Medical Meetings

Apr 17, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Announces Presentations at Upcoming Medical Meetings

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

Apr 1, 2025, 7:00 AM EDT - 1 year ago

CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

Mar 27, 2025, 7:00 AM EDT - 1 year ago

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Secures Credit Facility for Up to $32.5 Million

Mar 5, 2025, 7:00 AM EST - 1 year ago

CalciMedica Secures Credit Facility for Up to $32.5 Million

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

Mar 4, 2025, 7:00 AM EST - 1 year ago

CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

Feb 19, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 4:05 PM EST - 1 year ago

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

Jan 14, 2025, 7:00 AM EST - 1 year ago

CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 21, 2024, 8:00 AM EST - 1 year ago

CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Nov 13, 2024, 7:00 AM EST - 1 year ago

CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

Nov 7, 2024, 7:00 AM EST - 1 year ago

CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer

CalciMedica Announces Pricing of Public Offering of Common Stock

Oct 30, 2024, 10:11 PM EDT - 1 year ago

CalciMedica Announces Pricing of Public Offering of Common Stock

CalciMedica Announces Proposed Public Offering of Common Stock

Oct 30, 2024, 4:50 PM EDT - 1 year ago

CalciMedica Announces Proposed Public Offering of Common Stock

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 30, 2024, 7:00 AM EDT - 1 year ago

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Oct 28, 2024, 4:05 PM EDT - 1 year ago

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

Aug 12, 2024, 4:10 PM EDT - 2 years ago

CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Proxy statement: Proxy Filing

Jul 16, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Proxy statement: Proxy Filing

CalciMedica Proxy statement: Proxy Filing

Jul 16, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Proxy statement: Proxy Filing

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

Jul 9, 2024, 7:30 AM EDT - 2 years ago

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

Jul 8, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences

CalciMedica Set to Join Russell Microcap® Index

Jul 1, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Set to Join Russell Microcap® Index

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 27, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Jun 26, 2024, 4:05 PM EDT - 2 years ago

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

May 13, 2024, 4:05 PM EDT - 2 years ago

CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

May 7, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

Apr 24, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

Mar 28, 2024, 7:00 AM EDT - 2 years ago

CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Mar 13, 2024, 8:00 AM EDT - 2 years ago

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Feb 28, 2024, 6:57 PM EST - 2 years ago

CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Feb 13, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 7, 2024, 4:05 PM EST - 2 years ago

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CalciMedica Registration statement: Registration Filing

Jan 31, 2024, 7:00 AM EST - 2 years ago

CalciMedica Registration statement: Registration Filing

CalciMedica Announces Private Placement of up to Approximately $55 Million

Jan 22, 2024, 8:00 AM EST - 2 years ago

CalciMedica Announces Private Placement of up to Approximately $55 Million

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Nov 9, 2023, 7:00 AM EST - 2 years ago

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Nov 2, 2023, 9:15 AM EDT - 2 years ago

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

CalciMedica Announces Upcoming Presentations and Events in September

Sep 6, 2023, 7:30 AM EDT - 3 years ago

CalciMedica Announces Upcoming Presentations and Events in September

Zardiw
Zardiw Jun. 28 at 5:12 PM
#DDAmanda Chart on $TSLA. Your thoughts? Watching these too: $ILLR $CALC $LVWR Check our 4th of July Special! https://DDAmanda.com
0 · Reply
Dan_o
Dan_o Jun. 28 at 12:51 PM
$CALC Part 1 - To follow is an email I sent to $CALC investor relations back in Feb. when the stock price crashed. I shared the story of $RZLT that recently crashed from $10 to $1 after a lead trial failed . Their management and board showed confidence by buying more shares. $RZLT is still developing a pipeline and has ZERO, $0, revenue. Their stock price is now $5 a share. I will be a buyer at market open on Monday and will hold my position. The next immediate catalyst will be staying over $1 for ten days.
0 · Reply
Dan_o
Dan_o Jun. 28 at 12:50 PM
$CALC Part 2 - Email: I cannot think of a more motivated group of people than the current $CALC management. You own 52% of the shares. Before the dip the value was $37 mil and current value is $4 mil. I estimate you collectively have a cost bases of about $18 mil. If you could only learn from Rezolute Inc., $RZLT, management. Their share price dropped from $10 to $1 in December in less than one day. Management stepped in and purchased the stock at a deep discount like I am doing. In a little over a month and a half the Rezolute price per share peaked at $4 and is holding above $3.5 a share.
0 · Reply
MikeCaymanTrades
MikeCaymanTrades Jun. 27 at 8:38 PM
$CALC big open gap above 1.00
0 · Reply
Zardiw
Zardiw Jun. 27 at 5:29 PM
$SDOT - #DDAmanda Chart. Not making a call on this one, just sharing what the scanner found. Also keeping an eye on: $ARL $WSHP $CALC Check our 4th of July Special! https://DDAmanda.com
1 · Reply
Zardiw
Zardiw Jun. 27 at 4:58 PM
#DDAmanda Chart on $INLF. Setting up or breaking down? Also keeping an eye on: $SDOT $CALC $RYOJ Check our 4th of July Special! https://DDAmanda.com
0 · Reply
pablo4
pablo4 Jun. 26 at 9:32 PM
$CALC I'm resharing one of my 3 back to back posts from last night. IMO, today's action was to be expected. Although it was a pleasant surprise being so soon...the next day, the buyers were bound to step in. Management showed its willingness to risk more of its own capital on this science (business). That was not to be ignored....IMO!
0 · Reply
topstockalerts
topstockalerts Jun. 26 at 8:36 PM
$CALC this one earned a closer look today
0 · Reply
pablo4
pablo4 Jun. 26 at 8:10 PM
$CALC Fidelity shows a close of .8159.
1 · Reply
MUBSN
MUBSN Jun. 26 at 7:44 PM
$CALC there we go
1 · Reply
OffComesTheShirt
OffComesTheShirt Jun. 26 at 7:26 PM
$CALC 25%! We've got a runner today, boys.
0 · Reply
keokeostwiz
keokeostwiz Jun. 26 at 7:11 PM
$CALC Stubborn defense of .80…until it folds…..GL
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 26 at 7:03 PM
$CALC Taking to dollar land
0 · Reply
OffComesTheShirt
OffComesTheShirt Jun. 26 at 6:51 PM
$CALC 21% Off Comes The Underwear! Now it's a party.
0 · Reply
SUGONDEEZNUTS
SUGONDEEZNUTS Jun. 26 at 5:33 PM
$CALC
0 · Reply
MUBSN
MUBSN Jun. 26 at 5:29 PM
$CALC I think we will see a spike once crossing 0.8 We have our way clear to be able to fill the huge gap!
1 · Reply
DipBuyInvester
DipBuyInvester Jun. 26 at 5:12 PM
$CALC to dollar land!!
0 · Reply
DipBuyInvester
DipBuyInvester Jun. 26 at 5:00 PM
$CALC Slow and steady wins the race!!
1 · Reply
keokeostwiz
keokeostwiz Jun. 26 at 4:59 PM
$CALC Traversing city traffic but all the traffic signals flash green…GL
0 · Reply
66Caprice327
66Caprice327 Jun. 26 at 4:01 PM
$CALC Pretty sexy 4hr interval on the weekly. RSI and MACD curling nicely. GL ✊🏻
0 · Reply
MUBSN
MUBSN Jun. 26 at 3:50 PM
$CALC
1 · Reply
coiler123
coiler123 Jun. 26 at 3:23 PM
$CALC For the people who held through that sub 60 cent bs cheers.
1 · Reply